[ad_1]
THE US Food and Drug Administration said on Tuesday (Jul 2) it had warned a website called ozempen.com against unlawfully selling versions of Novo Nordisk’s weight-loss drugs.
Surging demand has outpaced supply for Novo’s Ozempic, Eli Lilly’s Mounjaro and other GLP-1 drugs that promote weight loss, fueling a growing global market for counterfeit versions.
The FDA said the website was offering unapproved versions of obesity and diabetes drugs Ozempic and Wegovy.
“These products are only available pursuant to a prescription from a licenced practitioner,” the health regulator said.
Last month, the World Health Organization issued warnings on fake drugs claiming to contain the active ingredient found in Ozempic and Wegovy.
Lilly and Novo have sued several entities to stop them from selling products claiming to contain the active ingredients tirzepatide and semaglutide that are used in their respective popular diabetes and weight-loss drugs. REUTERS
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
[ad_2]
Source link
